Novel Targets for Antimicrobials

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) is a growing global health crisis, complicating the treatment of microbial infections.
• A key mechanism of AMR involves alterations in the molecular targets of antimicrobial drugs.
• Identifying novel microbial targets and developing corresponding inhibitors is crucial for combating AMR.

Purpose of the Study:

• To review bacterial fatty acid biosynthesis (FAB) as a promising target for novel antimicrobial development.
• To explore potential inhibitors targeting the type II fatty acid synthesis (FAS) system.
• To highlight lead compounds discovered through high-throughput screening for antibacterial drug development.

Main Methods:

• Literature review focusing on bacterial FAB pathways and inhibitors.
• Analysis of established and emerging molecular targets in microbial resistance.
• Examination of drug discovery approaches, including high-throughput screening.

Main Results:

• Fatty acid biosynthesis (FAB) and its enzymes represent a highly attractive target for new antimicrobial agents.
• Several inhibitors targeting bacterial fatty acid synthesis (FAS) have been developed, with some in clinical use.
• Compounds like Platencimycin and Platencin, identified via screening, serve as valuable lead compounds for novel antibacterials.

Conclusions:

• Targeting bacterial FAB, particularly the type II FAS system, is a viable strategy to overcome AMR.
• Further exploration of FAB inhibitors holds significant potential for developing next-generation antibacterial drugs.
• Continued research into novel molecular targets and screening methods is essential for addressing the AMR challenge.